Abstract
Background Several COVID-19 vaccines are currently being deployed but supply constraints, concerns over durability of immune responses, solidifying vaccine hesitancy/resistance and vaccine efficacy in the face of emerging variants mean that new vaccines continue to be needed to fight the ongoing pandemic. The vaccine described here is an enveloped, coronavirus-like particle produced in plants (CoVLP) that displays the prefusion-stabilized spike (S) glycoprotein of SARS-CoV-2 (ancestral Wuhan strain) and is adjuvanted with AS03 (CoVLP+AS03).
Methods This Phase 3 randomized, observer-blind, placebo-controlled trial was conducted at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. Adults ≥18 years of age including those at high risk for COVID-19 complications were randomly assigned 1:1 to receive two intramuscular injections of CoVLP (3.75 μg) adjuvanted with AS03 or placebo, 21 days apart. The primary efficacy endpoint was prevention of symptomatic (≥ 1 symptom), PCR-confirmed SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of ≥160 virologically-confirmed cases. Tolerability and safety of CoVLP+AS03 were also determined.
Results A total of 24,141 volunteers were randomly assigned 1:1 to receive vaccine or placebo (N= 12,074 and 12,067, respectively: median age 29, range 18 to 86 years). Overall, 83% received both doses. 14.8% were SARS-CoV-2 seropositive at baseline. Symptomatic SARS-CoV-2 infection was confirmed in 165 study participants in the intention to treat (ITT) set and 157 in the per-protocol population (PP) set. Of the 157 in the PP set, 118 COVID-19 cases were in the placebo group and 39 COVID-19 cases were in the CoVLP+AS03 group for an overall vaccine efficacy (VE) of 71.0% (95% confidence interval (CI) 58.6, 80.0). Moderate-to-severe COVID-19 occurred in 8 and 32 participants in the CoVLP+AS03 and placebo groups, respectively: VE 78.1% (95% CI: 53.9, 90.5) in the PP set overall and 84.5% (95% CI: 62.0, 94.7) in those seronegative at recruitment.
To date, 100% of the sequenced strains (122/165 cases: 73.39%) were variants, dominated by Delta (45.9%) and Gamma (43.4%) strains. Vaccine efficacy by variant was 75.3% (95% CI 52.8, 87.9) against Delta and 88.6% (95% CI 74.6, 95.6) against Gamma. Cross-protection was also observed against Alpha, Lambda and Mu variants; although fewer cases were identified, all were in the placebo group. At diagnosis, viral loads in the CoVLP+AS03 breakthrough cases were >100-fold lower than in the placebo cases. Reactogenicity data for solicited adverse events (AEs) was analysed for a subset (N=4,136 in vaccine arm and N=3,683 for placebo) of participants. Reactogenicity was mostly mild to moderate, and transient, and occurred more frequently in the CoVLP+AS03 group. The safety analysis set used for unsolicited AE assessment comprised 24,076 participants who received at least one study injection: 12,036 received CoVLP+AS03 and 12,040 received placebo. All serious adverse events were assessed as unrelated, except two events reported in the same subject in the placebo group. No significant imbalance or safety concern was noted in medically attended AEs (MAAEs), adverse event of special interest (AESIs), AEs leading to withdrawal, deaths, or adverse events potentially associated with currently authorized vaccines.
Conclusions The CoVLP+AS03 vaccine candidate conferred an efficacy of 71.0% in preventing symptomatic SARS-CoV-2 infection caused by a spectrum of variants. Vaccine efficacy of 78.1% was observed against moderate and severe disease, while variant-specific efficacy ranged from 75.3% to 100%. Markedly lower viral loads in the CoVLP+AS03 group at the time of diagnosis suggests a significant virologic impact of vaccination even in the breakthrough cases. CoVLP+AS03 vaccine candidate was well tolerated, and no safety concerns were identified during the study. If approved by regulators, this more traditional protein+adjuvant vaccine produced using the novel plant-based platform may be able to make an important contribution to the global struggle against the increasingly complex family of SARS-CoV-2 viruses (Funded by Medicago with grants from the governments of Quebec and Canada; NCT04636697).
Competing Interest Statement
During the period of the study KJH, PG, GH, AIM, SP, KB, JA, IB, JD, NC, MC, JJW, NL, SL, AL, AM, EP, JP, PS, AS, LT, JN, MAD, ST, YK, BJW were either employees of Medicago Inc. or received salary support from Medicago Inc. TB, MAC, MK, FR are employed by the GlaxoSmithKline (GSK) group of companies and hold restricted shares in the group of companies. LHM received compensation from Medicago as a consultant.
Clinical Trial
NCT04636697
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04636697
Funding Statement
The study was sponsored by Medicago Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial is being conducted in accordance with current International Conference on Harmonization (ICH) guidelines on Good Clinical Practice, and applicable country specific regulatory requirements. All participants provided written informed consent before being enrolled. An independent Institutional Review Board (IRB) or Ethics Committee (EC) approved the protocol, protocol amendments and consent forms: Advarra IRB, USA and Canada, McGill University Health Centre Research Ethics Board, Canada, Health Research Ethics Board of Alberta Clinical Trials Committee, Canada, Comite de Etica en Investigacion (CEIINAPSI), Argentina, Comite Institucional de Revision de Ensayos Clinicos (CIREC) delHospital Militar Central Cir My Dr Cosme Argerich, Argentina, Comite Institucional de Etica de Investigacion en Salud, Sanatorio Allende, Argentina, Comite Independiente de Etica (CIE) para Ensayos en Farmacologia Clinica Prof. Luis M. Zieher, Argentina, Comite de Etica Centro de Osteopatias Medicas (CECOM), Argentina, Comite de Etica em Pesquisa da Faculdade de Medicina de Jundiai, Brazil, Comite de Etica em Pesquisa do Hospital Paranaense de Otorrinolaringologia IPO, Brazil, Comite de Etica em Pesquisa da Faculdade de Medicina de Sao Jose do Rio Preto FAMERP, Brazil, Comite de Etica em Pesquisa da Santa Casa de Misericordia de Belo Horizonte SCMBH, Brazil, Comite de Etica em Pesquisa do Instituto de Cardiologia do Distrito Federal ICDF, Brazil, Comite de Etica em Pesquisa do Hospital ProCardiaco Esho Empresa de Servicos Hospitalares/HPC, Brazil, Comite de Etica em Pesquisa do Hospital Moinhos de Vento HMV, Brazil, Comissao Nacional de Etica em Pesquisa CONEP, Brazil, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Mexico, Comite de Etica en Investigacion del Hospital La Mision, Mexico, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos, Mexico, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos, Mexico, Comite de Etica en Investigacion del Hospital General de Culiacan, Dr. Bernardo J. Gastelum, Mexico, Comite de Etica en Investigacion del Hospital SMIQ, S. de R.L. de C.V, Mexico, Comite de Investigacion de SMIQ, S.de R.L. de C.V, Mexico, Investigacion Biomedica para elDesarrollo de Farmacos S.A. de C.V., Mexico, and LondonFulham Research Ethics Committee, UK. Safety and efficacy data, as required by protocol, was reviewed by an Independent Data Monitoring Committee (IDMC) as needed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Medicago Inc. is committed to providing access to anonymized data collected during the trial that underlie the results reported in this article, at the end of the clinical trial, which is currently scheduled to be 1 year after the last participant is enrolled, unless granted an extension. Medicago Inc. will collaborate with its partner (GlaxoSmithKline, Wavre, Belgium) on such requests before disclosure. Proposals should be directed to wardb{at}medicago.com or daoustma{at}medicago.com. To gain access, data requestors will need to sign a data access agreement and access will be granted for non-commercial research purposes only.
